Interpretation of the functions, efficacy and clinical application of Tepotinib (Tuodekang)

Tepotinib is an oral small molecule tyrosine kinase inhibitor that mainly targets the abnormal activation of stromal cell-derived growth factor receptor (MET). METGene abnormalities, including exon 14 skipping mutations (MET exon 14 skipping mutation) or MET gene amplification is an important driver of non-small cell lung cancer (NSCLC) and other solid tumors. Tepotinib selectively inhibits the MET signaling pathway and blocks the downstream RAS/MAPK and PI3K/AKT pathways, thereby inhibiting tumor cell proliferation, migration and invasion, and achieving targeted anti-tumor effects.

Tepotinib is mainly used for patients with locally advanced or metastatic non-small cell lung cancer who carryMETexon14 skipping mutations. Clinical trials have shown that the drug can significantly improve the objective response rate (ORR) and progression-free survival (PFS), especially for patients who have received first-line treatment or have previously received chemotherapy. In addition, tepotinib also shows certain penetration in patients with brain metastases, which can control intracranial lesions to a certain extent and improve patients' quality of life.

Tepotinib has the advantages of strong targeting, controllable side effects, and convenient oral administration in clinical applications. Compared with traditional chemotherapy, it is more selective for tumor cells, reduces damage to normal cells, and reduces hematological toxicity and gastrointestinal adverse reactions. Patients can generally maintain a good quality of life while taking the medication, and at the same time, the dosage can be flexibly adjusted to cope with mild to moderate side effects.

Before using tepotinib, patients should undergo genetic testing to confirm MET exon 14 skipping mutation or MET amplification. During the treatment process, regular imaging review and hematology monitoring are required to evaluate the efficacy and safety. For patients who experience adverse reactions such as pulmonary infection, abnormal liver function, or edema, the dose should be adjusted in a timely manner or symptomatic treatment should be taken. As more clinical data accumulates, tepotinib is expected to play a broader role in MET-driven precision cancer treatment.

Reference link:https://www.drugs.com